Chrono Therapeutics is focused on improving clinical outcomes for patients battling addictions and living with neurological disorders via our proprietary Integrated Dosing Solution, pioneering a new era of transdermal drug delivery designed to meet each patient's individual needs.
We integrate timed drug delivery with personalized, mobile-phone-based digital support and unique data analytics to maximize compliance, help patients manage hard to treat conditions and optimize clinical outcomes.
Our transdermal system provides the right amount of drug at the right time to maximize a drug's effectiveness. In contrast, standard medication patches deliver an inflexible dosing profile, regardless of when an individual patient may or may not need medication.
Integrated Dosing Solution:
Transdermal drug delivery has significant benefits over oral medications.
Benefits include no GI absorption or drug-food interactions, no liver metabolism, as well as better and more accurate compliance with less chance of incorrect dosing.
We build on these benefits by first adding programmable dosing customized to the disorder, so medication is timed to peak symptoms and reduced when not needed. Three additional technologies – compliance monitoring to catch lapses before they become a problem, behavioral support to keep people on track towards their goal, and data analytics to understand patterns – are added to uniquely converge four technologies in order to optimize outcomes.
Timed Drug Delivery
Standard medication patches deliver an inflexible daily dosing profile. But for many indications, patients need a customized dosing profile, with just the right amount of medication at specific times throughout the day. This is where Chrono excels.
When transdermal medication is optimally tuned to a patient's needs, patients manage when and how much medication they receive to optimally control their condition.
Based on cutting-edge behavior change science (Acceptance Commitment Therapy and Cognitive Behavior Therapy) and developed with leading experts from top institutions, our mobile app ensures people stay on track. Our behavioral support comprises four aspects:
A robust notification engine makes sure we reach people at just the right time with the right triggers to take action.
Clinically Tested Education
Our curriculums are developed with recognized experts and tailored to our patients' needs and education levels.
Our wearable button provides an immediate and convenient way to trigger help on the mobile application, reducing relapse.
Understanding and leveraging a patient's unique motivators and support network is what drives successful outcomes.
Compliance Monitoring and Assistance
We know that routines matter, so our solution is designed to fit into existing daily patterns, with simple adjustments needed only at bedtime. We believe that this emphasis on ease of use and sensitivity to established daily life may help improve compliance and potentially treatment outcomes.
As a safety net, embedded sensors and digital reminders are there to help people stay on track. The sensors can also be configured to alert a person's support network when someone needs extra support.
To help patients progress, the system provides real-time analytical feedback. This includes content such as days used, circumstances around when the wearable help button is triggered, etc.
Aggregated de-identified data is delivered via a secure HIPAA compliant infrastructure, providing health systems with the potential to successfully administer treatments, programs and benefits. This means changing the nature of healthcare, and profoundly affecting a therapy's potential.
We have multiple programs in active development that address significant market opportunities with unmet needs.
Each of our programs leverages medications that readily cross the skin. In addition to the programs currently in development, our discovery pipeline is robust, with a number of CNS indications under evaluation that would benefit from a therapeutic combined with behavioral and compliance support.
CTI-100: Nicotine cessation
Cigarettes and e-cigarettes are highly addictive, and are one of the world’s biggest preventable health challenges. Our first application delivers a complete 10-week, clinically tested nicotine cessation program to help people quit for good.
CTI-200: Dyskinesia in Parkinson's Disease
Optimizing the timing and dosing of Parkinson’s Disease medications is absolutely essential to improving outcomes for patients. We are developing a novel integrated solution that delivers the right amount of medication at the right times to minimize off time and dyskinesias induced by chronic levodopa use, while simultaneously providing patient support and connectivity to caregivers and health care professionals.
CTI-300: Prescription Opioid use Disorder
While opioids help many patients control pain, they are highly addictive and currently kill more than 115 Americans daily due to overdoses. We urgently need better ways to safely take and then stop taking pain medication. We are developing a novel approach to treating opioid dependence that helps patients take the right amount of drug to control withdrawal symptoms and successfully taper use.